Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Buffers and Standards
  4. Chromatography Standards
  5. Drug Standards
  6. 111015687

Temozolomide Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™

Catalog No. 111015687 Shop All MilliporeSigma Supelco Products
Click to view available options
Quantity:
1 g

Description

Certified pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to pharmacopeia primary standards.Temozolomide is an alkylating agent of the imidazotetrazine group. It is a chemotherapy drug, used in the treatment of anaplastic astrocytoma, glioblastoma multiforme and malignant metastatic melanoma, which works by arresting cancer cell growth.
TRUSTED_SUSTAINABILITY

Specifications

CAS 85622-93-1
Purity Grade Notes These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
Linear Formula C6H6N6O2
MDL Number MFCD00866492
Synonym Temozolomide; 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide; 3-Methyl-4-oxo-8-imidazolo[5,1-d][1,2,3,5 ]tetrazinecarboxamide; 4-Methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0 ]nona-2,7,9-triene-9-carboxamide; 8-Carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one; NSC 362856
Type Certified Reference Material
Quantity 1 g
Formula Weight 194.15
Grade Certified Reference Material
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.